CTLA4 and central nervous system cancer: This novel approach allows the compatibility with blocking antibodies for other immune checkpoints (such as anti-CTLA-4) as well as targeting gliomas, since the patch could be directly delivered to the capillary bed within the brain, bypassing the blood-brain barrier.